Journal of Genetic Medicine

Korean Society of Medical Genetics and Genomics (대한의학유전학회)
권호 표지
DOI QR코드

DOI QR Code

Mutation spectrum of NF1 gene in Korean unrelated patients with neurofibromatosis 1: Six novel pathogenic variants

  • Received : 2024.05.13
  • Accepted : 2024.06.24
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Neurofibromatosis 1 (NF1) is one of the most common autosomal dominant diseases caused by heterozygous mutation in the NF1 gene. Mutation detection is complex owing to the large size of the NF1 gene, the presence of a high number of partial pseudogenes, and the great variety of mutations. We aimed to study the mutation spectrum of NF1 gene in Korean patients with NF1. Materials and Methods: We have analyzed total 69 unrelated patients who were clinically diagnosed with NF1. PCR and sequencing of the NF1 gene was performed in all unrelated index patients. Additionally, multiplex ligation-dependent probe amplification (MLPA) test of the NF1 and SPRED1 gene analysis (sequencing and MLPA test) were performed in patients with negative results from NF1 gene sequencing analysis. Results: Fifty-five different variants were identified in 60 individuals, including six novel variants. The mutations included 36 single base substitutions (15 missense and 21 nonsense), eight splicing mutations, 13 small insertion or deletions, and three gross deletions. Most pathogenic variants were unique. The mutations were evenly distributed across exon one through 58 of NF1, and no mutational hot spots were found. When fulfilling the National Institutes of Health criterion for the clinical diagnosis of NF1, the detection rate was 84.1%. Cafe-au-lait macules were observed in all patients with NF1 mutations. There is no clear relationship between specific mutations and clinical features. Conclusion: This study revealed a wide spectrum and genetic basis of patients with NF1 in Korea. Our results aim to contribute genetic management and counseling.

Keywords

References

  1. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers 2017;3:17004. 
  2. Uusitalo E, Rantanen M, Kallionpaa RA, Poyhonen M, Leppavirta J, Yla-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol 2016;34:1978-86.  https://doi.org/10.1200/JCO.2015.65.3576
  3. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575-8.  https://doi.org/10.1001/archneur.1988.00520290115023
  4. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021;23:1506-13. 
  5. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81-8.  https://doi.org/10.1136/jmg.2006.045906
  6. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63:851-9.  https://doi.org/10.1016/0092-8674(90)90151-4
  7. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990;63:843-9.  https://doi.org/10.1016/0092-8674(90)90150-D
  8. Valero MC, Pascual-Castroviejo I, Velasco E, Moreno F, HernandezChico C. Identification of de novo deletions at the NF1 gene: no preferential paternal origin and phenotypic analysis of patients. Hum Genet 1997;99:720-6.  https://doi.org/10.1007/s004390050438
  9. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000;15:541-55.  https://doi.org/10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N
  10. Kehrer-Sawatzki H, Kluwe L, Salamon J, Well L, Farschtschi S, Rosenbaum T, et al. Clinical characterization of children and adolescents with NF1 microdeletions. Childs Nerv Syst 2020;36:2297-310.  https://doi.org/10.1007/s00381-020-04717-0
  11. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007;39:1120-6.  https://doi.org/10.1038/ng2113
  12. Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 2009;302:2111-8.  https://doi.org/10.1001/jama.2009.1663
  13. Valero MC, Martin Y, Hernandez-Imaz E, Marina Hernandez A, Melean G, Valero AM, et al. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn 2011;13:113-22.  https://doi.org/10.1016/j.jmoldx.2010.09.002
  14. De Luca A, Bottillo I, Dasdia MC, Morella A, Lanari V, Bernardini L, et al. Deletions of NF1 gene and exons detected by multiplex ligationdependent probe amplification. J Med Genet 2007;44:800-8.  https://doi.org/10.1136/jmg.2007.053785
  15. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.  https://doi.org/10.1038/gim.2015.30
  16. van Minkelen R, van Bever Y, Kromosoeto JN, Withagen-Hermans CJ, Nieuwlaat A, Halley DJ, et al. A clinical and genetic overview of 18years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet 2014;85:318-27.  https://doi.org/10.1111/cge.12187
  17. Cali F, Chiavetta V, Ruggeri G, Piccione M, Selicorni A, Palazzo D, et al. Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGMTM platform. Eur J Med Genet 2017;60:93-9.  https://doi.org/10.1016/j.ejmg.2016.11.001
  18. Accetturo M, Bartolomeo N, Stella A. In-silico analysis of NF1 missense variants in ClinVar: translating variant predictions into variant interpretation and classification. Int J Mol Sci 2020;21:721. 
  19. Bottillo I, Torrente I, Lanari V, Pinna V, Giustini S, Divona L, et al. Germline mosaicism in neurofibromatosis type 1 due to a paternally derived multi-exon deletion. Am J Med Genet A 2010;152A:1467-73.  https://doi.org/10.1002/ajmg.a.33386
  20. Trevisson E, Forzan M, Salviati L, Clementi M. Neurofibromatosis type 1 in two siblings due to maternal germline mosaicism. Clin Genet 2014;85:386-9.  https://doi.org/10.1111/cge.12177
  21. Kang H, Lee J, Park J, Yim J, Chae H, Kim Y, et al. NF1 variant spectrum in Korean patients with neurofibromatosis type 1 disorder. Lab Med Online 2021;11:17-24.  https://doi.org/10.47429/lmo.2021.11.1.17
  22. Kang E, Kim YM, Seo GH, Oh A, Yoon HM, Ra YS, et al. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types. J Hum Genet 2020;65:79-89.  https://doi.org/10.1038/s10038-019-0695-0
  23. Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet 2003;40:e82. 
  24. Sabbagh A, Pasmant E, Imbard A, Luscan A, Soares M, Blanche H, et al. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat 2013;34:1510-8.  https://doi.org/10.1002/humu.22392
  25. Zhang J, Tong H, Fu X, Zhang Y, Liu J, Cheng R, et al. Molecular characterization of NF1 and neurofibromatosis type 1 genotype-phenotype correlations in a Chinese population. Sci Rep 2015;5:11291. 
  26. Barrea C, Vaessen S, Bulk S, Harvengt J, Misson JP. Phenotype-genotype correlation in children with neurofibromatosis type 1. Neuropediatrics 2018;49:180-4.  https://doi.org/10.1055/s-0037-1620239
  27. Ko JM, Sohn YB, Jeong SY, Kim HJ, Messiaen LM. Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1. Pediatr Neurol 2013;48:447-53.  https://doi.org/10.1016/j.pediatrneurol.2013.02.004
  28. Jeong SY, Park SJ, Kim HJ. The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1. J Korean Med Sci 2006;21:107-12.  https://doi.org/10.3346/jkms.2006.21.1.107
  29. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.  https://doi.org/10.1016/0092-8674(90)90024-9
  30. Jang MA, Kim YE, Kim SK, Lee MK, Kim JW, Ki CS. Identification and characterization of NF1 splicing mutations in Korean patients with neurofibromatosis type 1. J Hum Genet 2016;61:705-9.  https://doi.org/10.1038/jhg.2016.33
  31. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009;123:124-33.  https://doi.org/10.1542/peds.2007-3204
  32. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 2013;115:939-55.  https://doi.org/10.1016/B978-0-444-52902-2.00053-9
  33. Bettegowda C, Upadhayaya M, Evans DG, Kim A, Mathios D, Hanemann CO; REiNS International Collaboration. Genotype-phenotype correlations in neurofibromatosis and their potential clinical use. Neurology 2021;97(7 Suppl 1):S91-8.  https://doi.org/10.1212/WNL.0000000000012436
  34. Kehrer-Sawatzki H, Cooper DN. Classification of NF1 microdeletions and its importance for establishing genotype/phenotype correlations in patients with NF1 microdeletions. Hum Genet 2021;140:1635-49.  https://doi.org/10.1007/s00439-021-02363-3
  35. Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, et al. Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848. Am J Hum Genet 2018;102:69-87.  https://doi.org/10.1016/j.ajhg.2017.12.001
  36. Koczkowska M, Callens T, Chen Y, Gomes A, Hicks AD, Sharp A, et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat 2020;41:299-315.  https://doi.org/10.1002/humu.23929